Jason D. Nosrati

Jason D. Nosrati

Radiation Oncology

1695 Eastchester Road
Bronx, NY 10461

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

A systematic review on frailty indices utilized in oncologic surgery and radiotherapy for metastatic spine disease: A critical appraisal of components and performance.

A systematic review on frailty indices utilized in oncologic surgery and radiotherapy for metastatic spine disease: A critical appraisal of components and performance.

Journal: North American Spine Society journal

Published: July 18, 2025

Treatment Terminations During Radiation Therapy: A 10-Year Experience.

Treatment Terminations During Radiation Therapy: A 10-Year Experience.

Journal: Practical radiation oncology

Published: December 26, 2023

Determining Combined Modality Dosimetric Constraints by Integration of IMRT and LDR Prostate Brachytherapy Dosimetry and Correlation with Toxicity.

Determining Combined Modality Dosimetric Constraints by Integration of IMRT and LDR Prostate Brachytherapy Dosimetry and Correlation with Toxicity.

Journal: Advances in radiation oncology

Published: October 07, 2022

Neoadjuvant Chemotherapy and Whole Ventricular Irradiation for Pure Intracranial Germinoma: A Comparison of Three Brain-Sparing Techniques.

Neoadjuvant Chemotherapy and Whole Ventricular Irradiation for Pure Intracranial Germinoma: A Comparison of Three Brain-Sparing Techniques.

Journal: Cureus

Published: April 07, 2021

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.

Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.

Journal: Targeted oncology

Published: September 02, 2019

JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.

JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.

Journal: British journal of haematology

Published: April 12, 2019

Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.

Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.

Journal: Urologic oncology

Published: October 04, 2018

The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.

The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.

Journal: Annals of hematology

Published: July 30, 2018

Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.

Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.

Journal: European journal of haematology

Published: March 02, 2018

Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.

Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 27, 2018

A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications.

A quantitative analysis of craniopharyngioma cyst expansion during and after radiation therapy and surgical implications.

Journal: Neurosurgical focus

Published: December 02, 2016

Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.

Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.

Journal: European journal of haematology

Published: February 10, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026